281 related articles for article (PubMed ID: 12798712)
1. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy.
Giuntoli RL; Metzinger DS; DiMarco CS; Cha SS; Sloan JA; Keeney GL; Gostout BS
Gynecol Oncol; 2003 Jun; 89(3):460-9. PubMed ID: 12798712
[TBL] [Abstract][Full Text] [Related]
2. Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study.
Seagle BL; Sobecki-Rausch J; Strohl AE; Shilpi A; Grace A; Shahabi S
Gynecol Oncol; 2017 Apr; 145(1):61-70. PubMed ID: 28317559
[TBL] [Abstract][Full Text] [Related]
3. Safety of ovarian preservation in premenopausal women with stage I uterine sarcoma.
Nasioudis D; Chapman-Davis E; Frey M; Holcomb K
J Gynecol Oncol; 2017 Jul; 28(4):e46. PubMed ID: 28541635
[TBL] [Abstract][Full Text] [Related]
4. Comparison of current staging systems and a novel staging system for uterine leiomyosarcoma.
Giuntoli RL; Lessard-Anderson CR; Gerardi MA; Kushnir CL; Cliby WA; Metzinger DS; Gostout BS
Int J Gynecol Cancer; 2013 Jun; 23(5):869-76. PubMed ID: 23669444
[TBL] [Abstract][Full Text] [Related]
5. Impact of adjuvant treatment on oncologic outcomes in patients with stage I leiomyosarcoma of the uterus.
Boyraz G; Başaran D; Salman MC; Özgül N; Yüce K
Turk J Med Sci; 2017 Jun; 47(3):841-846. PubMed ID: 28618731
[TBL] [Abstract][Full Text] [Related]
6. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma.
Giuntoli RL; Garrett-Mayer E; Bristow RE; Gostout BS
Gynecol Oncol; 2007 Jul; 106(1):82-8. PubMed ID: 17434579
[TBL] [Abstract][Full Text] [Related]
7. Trends in the treatment of uterine leiomyosarcoma in the Medicare population.
Foley OW; Rauh-Hain JA; Clemmer J; Clark RM; Hall T; Diver EJ; Schorge JO; del Carmen MG
Int J Gynecol Cancer; 2015 Mar; 25(3):453-8. PubMed ID: 25628107
[TBL] [Abstract][Full Text] [Related]
8. Uterine leiomyosarcoma: present management.
Giuntoli RL; Bristow RE
Curr Opin Oncol; 2004 Jul; 16(4):324-7. PubMed ID: 15187886
[TBL] [Abstract][Full Text] [Related]
9. Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: a 20-year experience.
Mahdavi A; Monk BJ; Ragazzo J; Hunter MI; Lentz SE; Vasilev SA; Tewari KS
Int J Gynecol Cancer; 2009 Aug; 19(6):1080-4. PubMed ID: 19820372
[TBL] [Abstract][Full Text] [Related]
10. Leiomyosarcoma: One disease or distinct biologic entities based on site of origin?
Worhunsky DJ; Gupta M; Gholami S; Tran TB; Ganjoo KN; van de Rijn M; Visser BC; Norton JA; Poultsides GA
J Surg Oncol; 2015 Jun; 111(7):808-12. PubMed ID: 25920434
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma.
Wu TI; Chang TC; Hsueh S; Hsu KH; Chou HH; Huang HJ; Lai CH
Gynecol Oncol; 2006 Jan; 100(1):166-72. PubMed ID: 16182349
[TBL] [Abstract][Full Text] [Related]
12. Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor.
Burghaus S; Halmen S; Gass P; Mehlhorn G; Schrauder MG; Lux MP; Renner SP; Beckmann MW; Hein A; Thiel FC
Arch Gynecol Obstet; 2016 Aug; 294(2):343-51. PubMed ID: 26711836
[TBL] [Abstract][Full Text] [Related]
13. Evaluating prognostic parameters in women with uterine leiomyosarcoma. A clinicopathologic study.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
J Reprod Med; 2003 Feb; 48(2):95-100. PubMed ID: 12621792
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007.
Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
J Cancer Res Clin Oncol; 2008 Dec; 134(12):1277-87. PubMed ID: 18506484
[TBL] [Abstract][Full Text] [Related]
15. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
16. Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus.
Leitao MM; Sonoda Y; Brennan MF; Barakat RR; Chi DS
Gynecol Oncol; 2003 Oct; 91(1):209-12. PubMed ID: 14529683
[TBL] [Abstract][Full Text] [Related]
17. Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand.
Potikul C; Tangjitgamol S; Khunnarong J; Srijaipracharoen S; Thavaramara T; Pataradool K
Asian Pac J Cancer Prev; 2016; 17(4):1759-67. PubMed ID: 27221849
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990-2001.
Koivisto-Korander R; Butzow R; Koivisto AM; Leminen A
Gynecol Oncol; 2008 Oct; 111(1):74-81. PubMed ID: 18657852
[TBL] [Abstract][Full Text] [Related]
19. Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?
Ricci S; Giuntoli RL; Eisenhauer E; Lopez MA; Krill L; Tanner EJ; Gehrig PA; Havrilesky LJ; Secord AA; Levinson K; Frasure H; Celano P; Fader AN
Gynecol Oncol; 2013 Dec; 131(3):629-33. PubMed ID: 24016408
[TBL] [Abstract][Full Text] [Related]
20. Factors Affecting Overall Survival in Premenopausal Women With Uterine Leiomyosarcoma: A Retrospective Analysis With Long-Term Follow-Up.
Singh N; Al-Ruwaisan M; Batra A; Itani D; Ghatage P
J Obstet Gynaecol Can; 2020 Dec; 42(12):1483-1488. PubMed ID: 32900677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
